Alveofact 50mg Injection

Alveofact 50mg Injection contains an active component called Phospholipid fraction from bovine lung. It is used as medication primarily in the treatment of respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs don't produce enough surfactant, a substance essential for maintaining the lungs' elasticity and preventing alveoli collapse. In severe cases of pneumonia, especially in premature infants or newborns, where lung function is compromised, this medication might be used to support breathing. In some cases, this medication might assist with lung function when babies pass stool (meconium) while still in the womb and inhale it into their lungs before or during delivery, causing breathing problems. Individuals with known severe allergies to components of the Alveofact 50mg Injection  or any of its components should not receive it. In some cases, active or severe infections may be a contraindication to this medication due to the potential risk of worsening the infection or complicating the treatment. It might not be recommended for infants above a certain gestational age or weight threshold, as their lung maturity might not benefit from this intervention.  If the patient has a severe bleeding disorder or an increased risk of bleeding, administering it may pose a risk of bleeding into the lungs or exacerbate bleeding issues, so should consult a healthcare provider before taking it. Alveofact 50mg Injection  is primarily used in neonatal care and is not typically administered to older adults.